First Bank & Trust Sells 11,755 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

First Bank & Trust cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,553 shares of the biopharmaceutical company’s stock after selling 11,755 shares during the quarter. Gilead Sciences makes up about 1.5% of First Bank & Trust’s investment portfolio, making the stock its 15th largest position. First Bank & Trust’s holdings in Gilead Sciences were worth $1,966,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Capital International Investors grew its position in Gilead Sciences by 336.8% during the 1st quarter. Capital International Investors now owns 56,369,657 shares of the biopharmaceutical company’s stock worth $4,214,200,000 after acquiring an additional 43,464,551 shares during the last quarter. Capital World Investors lifted its holdings in Gilead Sciences by 123.0% in the 1st quarter. Capital World Investors now owns 46,331,318 shares of the biopharmaceutical company’s stock worth $3,463,732,000 after buying an additional 25,555,467 shares during the period. Capital Research Global Investors lifted its holdings in Gilead Sciences by 12.7% in the 1st quarter. Capital Research Global Investors now owns 95,982,319 shares of the biopharmaceutical company’s stock worth $7,175,643,000 after buying an additional 10,849,434 shares during the period. APG Asset Management N.V. lifted its holdings in Gilead Sciences by 237.9% in the 1st quarter. APG Asset Management N.V. now owns 2,417,175 shares of the biopharmaceutical company’s stock worth $139,948,000 after buying an additional 1,701,818 shares during the period. Finally, First Trust Advisors LP lifted its holdings in Gilead Sciences by 110.8% in the 2nd quarter. First Trust Advisors LP now owns 3,237,076 shares of the biopharmaceutical company’s stock worth $249,061,000 after buying an additional 1,701,510 shares during the period. Hedge funds and other institutional investors own 78.74% of the company’s stock.

Several research firms have weighed in on GILD. Jefferies Financial Group reiterated a “buy” rating and issued a $97.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 21st. Oppenheimer restated a “buy” rating on shares of Gilead Sciences in a research note on Monday, May 18th. Robert W. Baird restated a “hold” rating and issued a $76.00 target price on shares of Gilead Sciences in a research note on Monday, June 29th. Royal Bank of Canada lowered their target price on Gilead Sciences from $89.00 to $87.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Piper Sandler lowered their target price on Gilead Sciences from $90.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and nine have assigned a buy rating to the company. Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $79.68.

NASDAQ:GILD traded up $0.74 during trading hours on Wednesday, reaching $68.84. 9,115,171 shares of the company traded hands, compared to its average volume of 16,452,303. The stock has a market capitalization of $86.31 billion, a P/E ratio of -286.28, a P/E/G ratio of 2.21 and a beta of 0.65. The business’s 50-day moving average price is $74.35 and its two-hundred day moving average price is $73.89. Gilead Sciences, Inc. has a 1 year low of $60.89 and a 1 year high of $85.97. The company has a current ratio of 2.33, a quick ratio of 2.23 and a debt-to-equity ratio of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.24 billion. Gilead Sciences had a positive return on equity of 33.59% and a negative net margin of 1.16%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 6.96 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be issued a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.95%. The ex-dividend date is Monday, September 14th. Gilead Sciences’s payout ratio is 44.30%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.